The Urokinase receptor, also known as urokinase plasminogen activator surface receptor (uPAR) or CD87 (C luster of D ifferentiation 87), is a protein encoded in humans by the PLAUR gene.

We identified CD87, CD44, CD49b, CD95, and Ly-6C as cancer-associated fibroblast cell surface markers, while CD39 was identified to mark normal fibroblasts from healthy tissues.

Dec 11, 2003 · The analysis of CD87 (urokinase-type plasminogen activator receptor – uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological …

Jul 8, 2024 · Recently, bispecific T-cell engagers (BiTEs) and chimeric antigen receptor-modified T cells (CAR-Ts) have been shown to have high therapeutic efficacy in hematological tumors. CD87 is …

Nov 4, 2025 · CD87, the receptor for the urokinase plasminogen activator (uPA), contributes to tumor progression and is highly upregulated in CRC. However, its expression is minimal in most normal …

Jun 29, 1999 · In the present report, we provide evidence that uPAR (CD87) is an important receptor for platelet kinetics, activation, and endothelium binding associated with inflammation.

Apr 8, 2022 · Urokinase-type plasminogen activator receptor (uPAR or CD87) is a glycosyl-phosphatidyl-inositol anchored (GPI) membrane protein. The uPAR primary ligand is the serine protease …

CD87 expression may have implications for diagnosing acute myeloblastic leukemia (AML) and determining its prognosis, as well as for fol-low-up of minimal residual disease (MRD).

Jan 1, 2022 · The study demonstrates that generated CAR-T lymphocytes manifest specific cytotoxicity towards target cells with both unmodified expression and overexpression of CD87 antigen in HeLa …

The analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, …